Clinical proof of concept trial of a Kv3 modulator for the treatment of tinnitus

More than 10% of adults live with tinnitus, a chronic ringing in the ears that has no approved drug treatment. Current options like counselling only help patients cope, not silence the sound. This clinical trial tests whether a novel drug called AUT00063—originally developed for age-related hearing loss—can actually reduce tinnitus symptoms. The drug works by modulating potassium ion channels in the brain, which are thought to be overactive in tinnitus. If the trial succeeds, it could become the first effective oral treatment for the condition, shifting the standard of care from symptom management to direct relief. The project is a collaboration between Autifony Therapeutics and Professor Deborah Hall at the University of Nottingham, a leading tinnitus expert. Success would mean millions of people could take a daily pill to quiet the phantom noise, rather than relying on sound therapy or psychological coping strategies. This is a proof-of-concept trial, so the immediate outcome is evidence of efficacy—not a market-ready drug—but it represents a major step toward a treatment where none currently exists.